Raymond James Financial
DYN icon

Raymond James Financial’s Dyne Therapeutics DYN Stock Holding History

Raymond James Financial’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.8M Buy
576,350
+124,706
+28% +$2.32M ﹤0.01% 1940
2026
Q1 		$8.19M Sell
451,644
-78,694
-15% -$1.36M ﹤0.01% 2183
2025
Q4 		$10.4M Buy
530,338
+453,426
+590% +$8.59M ﹤0.01% 1933
2025
Q3 		$973K Buy
76,912
+25,432
+49% +$290K ﹤0.01% 3689
2025
Q2 		$490K Sell
51,480
-1,613
-3% -$17.8K ﹤0.01% 4018
2025
Q1 		$555K Sell
53,093
-46,235
-47% -$661K ﹤0.01% 3879
2024
Q4 		$2.34M Buy
+99,328
New +$2.94M ﹤0.01% 2851

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Raymond James Financial's DYN Position: Q2 2026 in Review

Raymond James Financial increased its Dyne Therapeutics (DYN) stake by 28% in Q2 2026, buying an estimated $2.32M and bringing the position to 576,350 shares worth $12.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1940.

Raymond James Financial first reported a position in DYN in Q4 2024 and has held it in 7 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Raymond James Financial held 576,350 shares of Dyne Therapeutics worth $12.8M as of Q2 2026.
  • Raymond James Financial bought 124,706 Dyne Therapeutics shares in Q2 2026, an estimated $2.32M.
  • Dyne Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #1940 holding.
  • Raymond James Financial first reported a position in Dyne Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.